What happened to Actelion Pharmaceuticals?
The new company Idorsia was created from former Actelion drug discovery operations and early-stage clinical development assets and listed in June 2017 on the SIX Swiss Exchange….CoTherix.
| Type | Subsidiary |
|---|---|
| Industry | Pharmaceutical |
| Founded | 2000 |
| Defunct | 9 January 2007 |
| Fate | acquired by Actelion |
When was Actelion founded?
1997
Actelion/Founded
The Clozels founded Actelion in 1997, calling it a stroke of luck that Swiss drugmaker Roche ROG. S, their previous employer, discontinued its cardiovascular program.
Who bought Actelion Pharmaceuticals?
Johnson & Johnson
NEW BRUNSWICK, N.J. – June 16, 2017 – Johnson & Johnson (NYSE:JNJ) today announced the completion of the acquisition of Actelion Ltd for a total purchase price of approximately $30 billion in cash.
Is Actelion a public company?
Actelion, the Swiss biotechnology company based in Allschwill, hasannounced an initial public offering of some 1 million shares, up to April 5, at a price range of 230-270 Swiss francs ($138.85-$163.00) each.
Where is Actelion located?
Actelion Pharmaceuticals is headquartered in Allschwil, Switzerland and has 31 office locations across 29 countries.
Why did J&J buy Actelion?
A spokesperson for J&J said in a statement emailed to FiercePharma that the Actelion acquisition was immediately accretive to earnings per share and was consistent with the company’s overall strategy to pursue therapies for “patients with serious illnesses and significant unmet medical need.”
Is Janssen a subsidiary of J&J?
Janssen Pharmaceuticals is a pharmaceutical company headquartered in Beerse, Belgium, and wholly-owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen.
Where are the headquarters of Johnson and Johnson?
New Brunswick, NJ
Johnson & Johnson/Headquarters
How big is Johnson and Johnson?
Founded in 1886 in New Brunswick, New Jersey, Johnson & Johnson is one of the largest pharmaceutical, medical device, and consumer packaged goods manufacturers in the world. In 2020, the company generated some 82.6 billion U.S. dollars of total revenue.
What did J&J pay for Actelion?
But that was just the start of J&J’s troubles with Actelion, raising serious doubts that the final $30 billion price tag was worth it.
What does Actelion Ltd do?
Actelion Ltd operates as a pharmaceutical company. The Company focuses on discovery, development, and commercialization of drugs for diseases with significant medical needs includes pulmonary arterial hypertension (PAH) with treatments through oral, inhaled, and intravenous medications. Actelion serves patients globally.
How many drugs does Actelion have on the market?
Actelion currently has 10 compounds in its pipeline – including 3 in late-stage development – and 4 medicines on the market for orphan diseases : Tracleer (bosentan): Tracleer is one of Actelions best sellers and provides the most income to the company.
What happened to Actelion endothelin?
In 2006, the company established the Actelion Endothelin Research Award program which supports selected clinical research projects. In January 2017, Johnson & Johnson announced that it would purchase the company for $30 billion. Actelion’s research and development unit would also be spun off after the acquisition.
What happened to Actelion’s fasudil?
In January 2007, Actelion completed acquisition of all CoTherix stock, and summarily informed Asahi that work on fasudil would be terminated. Now, Actelion had a competitor blockbuster drug on the market, bosentan (Tracleer).